These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

146 related items for PubMed ID: 24472060

  • 21. The natural history of ALS is changing: improved survival.
    Qureshi M, Schoenfeld DA, Paliwal Y, Shui A, Cudkowicz ME.
    Amyotroph Lateral Scler; 2009; 10(5-6):324-31. PubMed ID: 19922119
    [Abstract] [Full Text] [Related]

  • 22. Evaluating emerging drugs in phase II & III for the treatment of amyotrophic lateral sclerosis.
    Li X, Bedlack R.
    Expert Opin Emerg Drugs; 2024 Jun; 29(2):93-102. PubMed ID: 38516735
    [Abstract] [Full Text] [Related]

  • 23. Amyotrophic lateral sclerosis: an update.
    de Carvalho M, Swash M.
    Curr Opin Neurol; 2011 Oct; 24(5):497-503. PubMed ID: 21725240
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. A post hoc analysis of subgroup outcomes and creatinine in the phase III clinical trial (EMPOWER) of dexpramipexole in ALS.
    Bozik ME, Mitsumoto H, Brooks BR, Rudnicki SA, Moore DH, Zhang B, Ludolph A, Cudkowicz ME, van den Berg LH, Mather J, Petzinger T, Archibald D.
    Amyotroph Lateral Scler Frontotemporal Degener; 2014 Sep; 15(5-6):406-13. PubMed ID: 25125035
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Adaptive Platform Trials to Transform Amyotrophic Lateral Sclerosis Therapy Development.
    Paganoni S, Berry JD, Quintana M, Macklin E, Saville BR, Detry MA, Chase M, Sherman AV, Yu H, Drake K, Andrews J, Shefner J, Chibnik LB, Vestrucci M, Cudkowicz ME, Healey ALS Platform Trial Study Group.
    Ann Neurol; 2022 Feb; 91(2):165-175. PubMed ID: 34935174
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. The Amyotrophic Lateral Sclerosis Functional Rating Scale. Assessment of activities of daily living in patients with amyotrophic lateral sclerosis. The ALS CNTF treatment study (ACTS) phase I-II Study Group.
    Arch Neurol; 1996 Feb; 53(2):141-7. PubMed ID: 8639063
    [Abstract] [Full Text] [Related]

  • 37. Can selection of rapidly progressing patients shorten clinical trials in amyotrophic lateral sclerosis?
    de Carvalho M, Swash M.
    Arch Neurol; 2006 Apr; 63(4):557-60. PubMed ID: 16606769
    [Abstract] [Full Text] [Related]

  • 38. Outcomes research in amyotrophic lateral sclerosis: lessons learned from the amyotrophic lateral sclerosis clinical assessment, research, and education database.
    Miller RG, Anderson F, Brooks BR, Mitsumoto H, Bradley WG, Ringel SP, ALS CARE Study Group.
    Ann Neurol; 2009 Jan; 65 Suppl 1():S24-8. PubMed ID: 19191307
    [Abstract] [Full Text] [Related]

  • 39. Amyotrophic lateral sclerosis--the tools of the trait.
    Lederer CW, Santama N.
    Biotechnol J; 2007 May; 2(5):608-21. PubMed ID: 17345579
    [Abstract] [Full Text] [Related]

  • 40. Quality-of-life assessment instruments used across ALS clinics.
    Mehta AK, Sarmet M, Maiser S, Meyer JA, Kolodziejczak S, Washington K, Simmons Z.
    Muscle Nerve; 2023 Nov; 68(6):865-872. PubMed ID: 37823580
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.